Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework

Rhea-AI Summary

Fresenius Medical Care (NYSE:FMS), the global leader in renal disease products and services, has announced the launch of a significant share buyback program. The company will initiate a first tranche of up to EUR 600 million, part of a larger EUR 1 billion total buyback program spanning two years.

The initial tranche is scheduled to complete by April 30, 2026, while the overall program will run until August 10, 2027. This initiative is a key component of FME's new capital allocation framework and FME Reignite strategy, aimed at enhancing shareholder value. The company serves approximately 300,000 dialysis patients through its network of 3,676 clinics worldwide.

Positive

• Implementation of EUR 600 million initial share buyback tranche, demonstrating strong commitment to shareholder returns
• Total buyback program of EUR 1 billion over two years shows significant capital return potential
• Program complements existing dividend policy, enhancing overall shareholder value proposition
• Strong market position as world's leading provider of renal disease products and services

Negative

• Significant cash outflow for buyback could impact available capital for business investments
• Extended program timeline until 2027 suggests gradual rather than immediate capital return

News Market Reaction

+0.17%

1 alert

+0.17% News Effect

On the day this news was published, FMS gained 0.17%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

• Total volume of the initial share buyback is up to EUR 1 billion over two years
• Share buyback to take place until August 10, 2027

BAD HOMBURG, Germany, Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which is part of its new capital allocation framework as presented at its Capital Markets Day on June 17. Today, the first tranche of up to EUR 600 million was initiated, which is planned to be completed at the latest by April 30, 2026.

"With the share buyback program, we are rapidly implementing an important component supporting our new FME Reignite strategy. The new program relates to initial share buybacks totaling EUR one billion over two years. This underscores our goal of reigniting value creation for shareholders and enables our shareholders to participate in the strength of our company," said Helen Giza, CEO of Fresenius Medical Care.

"The implementation of regular share buybacks in addition to a consistent dividend policy is part of our new capital allocation framework," stated Martin Fischer, CFO of Fresenius Medical Care.  

FME will provide regular updates on the progress of the share buyback program at https://freseniusmedicalcare.com/en/investors/shares/share-buy-back/.

About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,676 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 300,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company's website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media contact
Sven Jacobsen
T +49 171 28 79 127
sven.jacobsen@freseniusmedicalcare.com

Sabine Blessing
T +49 171 74 81 259
sabine.blessing@freseniusmedicalcare.com 

Contact for Analysts and Investors
Ilia Kürten 
T +49 6172 685 966
Ilia.kuerten@freseniusmedicalcare.com 

www.freseniusmedicalcare.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-announces-first-tranche-of-its-share-buyback-program-of-up-to-eur-600-million-as-part-of-its-new-capital-allocation-framework-302526291.html

SOURCE Fresenius Medical Care Holdings, Inc.

FAQ

What is the size of Fresenius Medical Care's (FMS) new share buyback program?

Fresenius Medical Care announced a total share buyback program of EUR 1 billion over two years, with the first tranche being up to EUR 600 million.

When will FMS complete the first tranche of its share buyback program?

The first tranche of up to EUR 600 million is planned to be completed by April 30, 2026.

How long will the entire FMS share buyback program run?

The complete share buyback program will run until August 10, 2027.

What is the purpose of Fresenius Medical Care's share buyback program?

The program is part of FME's new capital allocation framework and FME Reignite strategy, aimed at reigniting value creation for shareholders and allowing them to participate in the company's strength.

How many dialysis patients does Fresenius Medical Care serve globally?

Fresenius Medical Care serves approximately 300,000 patients through its network of 3,676 dialysis clinics worldwide.